A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer

Stopped This decision was conducted by the sponsor and not driven by safety concerns as no new safety signals have been observed in the ociperlimab program.

Conditions

• Non Small Cell Lung Cancer

Interventions

• DRUG: Tislelizumab
• DRUG: Durvalumab
• DRUG: Ociperlimab
• DRUG: Chemotherapy
• RADIATION: Radiotherapy

Sponsor

BeiGene